3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Sorafenib
29
Nivolumab
15
pembrolizumab
12
Radiosurgery
9
Bevacizumab
9
atezolizumab
7
regorafenib
5
Radiotherapy
5
Fluorouracil
5
Doxorubicin
5
lenvatinib
4
Sunitinib
4
Oxaliplatin
4
Ipilimumab
4
Gemcitabine
4
Ethiodized Oil
4
Erlotinib Hydrochloride
4
Capecitabine
4
TLC 388
3
Radiofrequency Ablation
3
Leucovorin
3
Everolimus
3
Cisplatin
3
Blood Specimen Collection
3
toripalimab
2
phosphomannopentaose sulfate
2
durvalumab
2
cediranib
2
avelumab
2
Tirapazamine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Carcinoma, Hepatocellular
×
High-Intensity Focused Ultrasound Ablation
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled